Efficacy and tolerability of pertuzumab containing neoadjuvant regimens versus doxorubicin and cyclophosphamide (AC) + paclitaxel (T) + trastuzumab (H) in patients with HER+ localised breast cancer

Trial Profile

Efficacy and tolerability of pertuzumab containing neoadjuvant regimens versus doxorubicin and cyclophosphamide (AC) + paclitaxel (T) + trastuzumab (H) in patients with HER+ localised breast cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Pertuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top